drugset / Trial / NCT00076544

Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain

NCT00076544 ↗

Phase 3 Completed 300 enrolled Elan Pharmaceuticals
Non-randomizedOpen-labelTreatment

Summary

The purpose of this open-label study is to give chronic severe pain patients with existing intrathecal pump systems access to ziconotide.

Timeline

Start
2004-02
Primary completion
2005-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziconotide Unknown — Intrathecal

Indications

No indication recorded.